K
Keiichi Masaki
Researcher at Hiroshima University
Publications - 33
Citations - 1353
Keiichi Masaki is an academic researcher from Hiroshima University. The author has contributed to research in topics: Sorafenib & Survival rate. The author has an hindex of 15, co-authored 32 publications receiving 958 citations. Previous affiliations of Keiichi Masaki include Life Sciences Institute.
Papers
More filters
Journal ArticleDOI
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
Thomas Karlas,David Petroff,Magali Sasso,Jian-Gao Fan,Yu Qiang Mi,Victor de Ledinghen,Manoj Kumar,Monica Lupsor-Platon,Kwang Hyub Han,Ana Carolina Cardoso,Giovanna Ferraioli,Wah-Kheong Chan,Vincent Wai-Sun Wong,Robert P. Myers,Kazuaki Chayama,Mireen Friedrich-Rust,Michel Beaugrand,Feng Shen,Jean Baptiste Hiriart,Shiv Kumar Sarin,Radu Badea,Kyu Sik Jung,Patrick Marcellin,Carlo Filice,Sanjiv Mahadeva,Grace Lai-Hung Wong,Pam Crotty,Keiichi Masaki,Joerg Bojunga,Pierre Bedossa,Volker Keim,Johannes Wiegand +31 more
TL;DR: CAP provides a standardized non-invasive measure of hepatic steatosis and factors such as the underlying disease, BMI and diabetes must be taken into account when interpreting CAP.
Journal ArticleDOI
Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma
Yohji Honda,Tomoki Kimura,Hiroshi Aikata,Tomoki Kobayashi,Takayuki Fukuhara,Keiichi Masaki,Takashi Nakahara,Noriaki Naeshiro,Atsushi Ono,Daisuke Miyaki,Yuko Nagaoki,Tomokazu Kawaoka,Shintaro Takaki,Akira Hiramatsu,Masaki Ishikawa,Hideaki Kakizawa,Masahiro Kenjo,Shoichi Takahashi,Kazuo Awai,Yasushi Nagata,Kazuaki Chayama +20 more
TL;DR: The tumor control and safety of stereotactic body radiation therapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) for small, solitary, and hypervascular hepatocellular carcinoma (HCC) with TACE alone is compared.
Journal ArticleDOI
Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases
Keiichi Masaki,Shintaro Takaki,Hideyuki Hyogo,Tomoki Kobayashi,Takayuki Fukuhara,Noriaki Naeshiro,Yoji Honda,Takashi Nakahara,Atsushi Ohno,Daisuke Miyaki,Eisuke Murakami,Yuko Nagaoki,Tomokazu Kawaoka,Masataka Tsuge,Nobuhiko Hiraga,Akira Hiramatsu,Michio Imamura,Yoshiiku Kawakami,Hiroshi Aikata,Hidenori Ochi,Shoichi Takahashi,Koji Arihiro,Kazuaki Chayama +22 more
TL;DR: The utility of CAP for diagnosing steatosis in patients with chronic liver disease is evaluated through prospectively evaluating the utility of controlled attenuation parameter with transient elastography.
Journal ArticleDOI
Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Yuko Nagaoki,Hiroshi Aikata,Norihito Nakano,Fumi Shinohara,Yuki Nakamura,Masahiro Hatooka,Kei Morio,Hiromi Kan,Hatsue Fujino,Tomoki Kobayashi,Takayuki Fukuhara,Keiichi Masaki,Atsushi Ono,Takashi Nakahara,Tomokazu Kawaoka,Daiki Miki,Masataka Tsuge,Akira Hiramatsu,Michio Imamura,Shoichi Takahashi,Yoshiiku Kawakami,Hidenori Ochi,Kazuaki Chayama +22 more
TL;DR: The risk factors for the development of hepatocellular carcinoma following successful eradication of hepatitis C virus with interferon therapy with IFN therapy in a long‐term, large‐scale cohort study are assessed.
Journal ArticleDOI
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Yuko Nagaoki,Michio Imamura,Hiroshi Aikata,Kana Daijo,Yuji Teraoka,Fumi Honda,Yuki Nakamura,Masahiro Hatooka,Reona Morio,Kei Morio,Hiromi Kan,Hatsue Fujino,Tomoki Kobayashi,Keiichi Masaki,Atsushi Ono,Takashi Nakahara,Tomokazu Kawaoka,Masataka Tsuge,Akira Hiramatsu,Yoshiiku Kawakami,C. Nelson Hayes,Daiki Miki,Hidenori Ochi,Kazuaki Chayama +23 more
TL;DR: Serum AFP levels decreased to similar levels between PEG-IFN/RBV and DCV/ASV groups following the achievement of viral eradication and Propensity score matching analysis showed no significant difference in HCC development rates between the two groups.